Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Sherman

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|July 14, 2018
Targeting VEGF and EGFR: a combination worth re-exploring?Vatche Tchekmedyian, Eric J Sherman
Cancer|June 5, 2020
Nasopharynx cancer: Induction or adjuvant? That is the questionNancy Y Lee, Eric J Sherman
JAMA Oncology|October 20, 2022
Methodologic Concerns in Secondary Analysis of KEYNOTE-048-ReplyYao Yu, Eric J Sherman, Nancy Y Lee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Reply to A.S. GardenNancy Y Lee, Eric J Sherman, Nadeem Riaz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?Nadeem Riaz, Eric J Sherman, Matthew Fury, et al.
Cancer|April 4, 2017
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinomaMona M Sabra, Eric J Sherman, R Michael Tuttle
JAMA Oncology|June 9, 2022
Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048Yao Yu, Kaveh Zakeri, Eric J Sherman, et al.
Cancers|August 26, 2023
<i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy ActivityAntoine Desilets, Matteo Repetto, Soo-Ryum Yang, et al.
Thyroid : Official Journal of the American Thyroid Association|March 6, 2020
Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted TherapiesTiffany Yeh, Michele Yeung, Eric J Sherman, et al.
Head & Neck|October 26, 2023
Rebuttal to comment on "Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer"James E Han, Kaveh Zakeri, Loren Michel, et al.
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|July 14, 2018
Targeting VEGF and EGFR: a combination worth re-exploring?Vatche Tchekmedyian, Eric J Sherman
Cancer|June 5, 2020
Nasopharynx cancer: Induction or adjuvant? That is the questionNancy Y Lee, Eric J Sherman
JAMA Oncology|October 20, 2022
Methodologic Concerns in Secondary Analysis of KEYNOTE-048-ReplyYao Yu, Eric J Sherman, Nancy Y Lee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Reply to A.S. GardenNancy Y Lee, Eric J Sherman, Nadeem Riaz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?Nadeem Riaz, Eric J Sherman, Matthew Fury, et al.
Cancer|April 4, 2017
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinomaMona M Sabra, Eric J Sherman, R Michael Tuttle
JAMA Oncology|June 9, 2022
Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048Yao Yu, Kaveh Zakeri, Eric J Sherman, et al.
Cancers|August 26, 2023
<i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy ActivityAntoine Desilets, Matteo Repetto, Soo-Ryum Yang, et al.
Thyroid : Official Journal of the American Thyroid Association|March 6, 2020
Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted TherapiesTiffany Yeh, Michele Yeung, Eric J Sherman, et al.
Head & Neck|October 26, 2023
Rebuttal to comment on "Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer"James E Han, Kaveh Zakeri, Loren Michel, et al.
Pageof 12